期刊
CLINICAL INFECTIOUS DISEASES
卷 73, 期 12, 页码 2329-2331出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa1064
关键词
tuberculosis; acquired drug resistance; bedaquiline; delamanid
资金
- Japan Agency for Medical Research and Development [JP20fk01081727]
This study reported a clinical case of simultaneous acquisition of resistance to bedaquiline and delamanid in Mycobacterium tuberculosis, with specific nucleotide insertions identified through whole genome sequencing. The minimum inhibitory concentrations for bedaquiline and delamanid were determined to be 0.25 μg/mL and >2.0 μg/mL, respectively.
This study is the first to report a clinical case of simultaneously acquired resistance to bedaquiline (BDQ) and delamanid (DLM). Whole genome sequencing revealed 2 nucleotide insertions (Rv0678 and fbiC) in the Mycobacterium tuberculosis isolate. The minimum inhibitory concentrations for BDQ and DLM were 0.25 mu g/mL and >2.0 mu g/mL, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据